Industry

USFDA gives nod for generic Lenalidomide capsules

Sun Pharma entered into a settlement with Celgene Corporation (Celgene) to resolve the patent litigation regarding Sun Pharma’s generic lenalidomide capsules.

The Health Master

February 10, 2023

160

Last Updated on October 10, 2024 by The Health Master

Sun Pharmaceutical Industries announced that one of its wholly owned subsidiaries has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for generic lenalidomide capsules (5 mg, 10 mg, 15 mg, 25 mg) and tentative approval for 2.5 mg, 20 mg.

The respective product approval is based on Revlimid capsules (5 mg, 10 mg, 15 mg, 25 mg, and 2.5 mg, 20 mg) as a reference product.

Click for more articles on USFDA

In June 2021, Sun Pharma entered into a settlement with Celgene Corporation (Celgene) to resolve the patent litigation regarding Sun Pharma’s generic lenalidomide capsules.

Pursuant to the terms of this settlement, Celgene granted Sun Pharma a license to Celgene’s patents required to manufacture and sell certain limited quantity of generic lenalidomide capsules in the US beginning sometime after March 2022.

In addition, the license allows Sun Pharma to manufacture and sell an unlimited quantity of generic lenalidomide capsules in the US beginning January 31, 2026.

Other drugs approval by USFDA

USFDA gives approval for Glycopyrrolate Injection USP

USFDA gives approval for Diclofenac Sodium Topical Solution USP

USFDA approves this anemia drug for patients on dialysis

USFDA gives nod for Technetium Mertiatide Injection

USFDA tentative nod for Dolutegravir, Emtricitabine and Tenofovir Alafenamide tablets

USFDA approves this drug for rare blood cancer

Also read

USFDA gives approval for Glycopyrrolate Injection USP

PCI issues notification on Exit Examination for D.Pharm course

Updated list of Medical Device Testing Laboratories (MDTLs)

Methotrexate may increased risk of skin cancer: Study